Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13749491 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRL3MBTL1MAPK1LMNA | |
| SCHEMBL13749480 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRL3MBTL1MAPK1LMNA | |
| SCHEMBL13750042 | 0.83 | POLB (0.54) | SMN1; SMN2 | |
| SCHEMBL13749632 | 0.83 | MEN1 (0.57) | SMN1; SMN2TSHRL3MBTL1MAPK1 | |
| SCHEMBL13749626 | 0.82 | TSHR (0.50) | SMN1; SMN2TSHRL3MBTL1MAPK1 | |
| SCHEMBL4326557 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2TSHRL3MBTL1MAPK1 | |
| SCHEMBL13749636 | 0.81 | HDAC6 (0.48) | SMN1; SMN2TSHRL3MBTL1 | |
| SCHEMBL13749630 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRL3MBTL1MAPK1LMNA | |
| SCHEMBL13750039 | 0.80 | TSHR (0.48) | SMN1; SMN2TSHRL3MBTL1LMNAHTT | |
| SCHEMBL13749628 | 0.80 | TSHR (0.58) | SMN1; SMN2TSHRL3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | SMN1; SMN2 2458/4885TSHR 4499/4885L3MBTL1 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.